Biology's Modern LIMS

Get breakthrough biomolecules through milestones faster





Shawna Wolverton

Chief Product Officer Benchling

Greetings!



Kate Quigley

Product Specialist Benchling

Our mission is to unlock the power of biotechnology

The world's most innovative biotech R&D organizations trust Benchling





Working with **1000** innovators across industries



Insights and expertise in accelerating biotech R&D





Leading biotech innovators are building on Benchling

1000+

biotechnology customers across industries using Benchling

22 of 50

of the largest biopharma companies trust Benchling to digitize their R&D

1 in **4**

biotech startups that went public in 2020 and 2021 were built on Benchling

200,000+

scientists around the globe use the Benchling R&D Cloud

R&D software hasn't kept up with science

R&D needs better technology to move at the new speed of science



Benchling R&D Cloud

Your central source of truth for biotech R&D

Data, collaboration, and insights on a trusted, open cloud platform

→ Scientifically-aware data model

Capture, centralize, and standardize R&D data at scale

→ Seamless collaboration

Enable teams across R&D to collaborate and get work done through a unified application suite

\rightarrow Better insights for faster decisions

Ask and answer questions with the ability to extract insights through point-and-click analytics

\rightarrow Trusted, open platform

Built to scale, maximizing security, compliance, and connectivity at every step of the way

÷	Results Dashboar	d > Strain Growth Assay					
q	► Run query	Control Strain • STRAIN001	Strain 1 • STRAIN013	Strain 2 • STRAIN050			
+	SQL				Schema browser	Search	
	1 SELECT 2 entity, 3 timepoint 4 od, 5 cell_dem 6 FROM indy.grv 7 WHERE entity	t_hr as "Time (hr)", sity/1000000 as "Cell Dens owth_assay\$raw = {{Control Strain}} or e	<pre>ab_research_5x5_rack ab_research_5x5_rack\$raw ab_research_10x10box ab_research_10x10box\$raw</pre>				
ф	or {{Stro 8 LIMIT 80	ain 1}} is null or {{Strai	ab_research_96_well_plate ab_research_96_well_plate\$ ab_research_384_well_plate ab_research_384_well_plate\$ raw				
2	Strain Growth Ass	ау					
		entity	Time (hr)	od	Cell Density x 1M	Chart type	
hlt	1	STRAIN001	0	0.01	8.26	III Table	
	2	• STRAIN001	2	0.11	50.86		
	3	• STRAINOO1	4	0.1871284765	83.716730989		
	4	• STRAIN001	6	0.5522342042	239.251770989		
	5	• STRAINOO1	8	0.566005131	245.118185806		
	6	STRAIN001	10	0.5663041617	245.245572884		
				T			

Disconnected, outdated systems across product lifecycle exacerbate friction

Legacy ELN

Lack workflow functionality

Not sample-centric

Struggle with structured data



Inefficient R&D knowledge transfer

Poor context for scientific decision support

Lack of shared sample traceability

Lack of shared processes and process management

Onerous IT management

Legacy LIMS

Built for small molecules

Disconnected information

Brittle

B



A unified solution for Research & Development teams

Reduce silos for data, workflows, and traceability



Benchling R&D Cloud



Legacy LIMS can't keep up with today's advanced biomolecule production and analysis.

Built for small molecules

LIMS were created before C>, ADCs, and RNA therapeutics began to demand novel product development methods. LIMS lack innovation required for these large, complex molecules.



Brittle

Processes created in LIMS have often outgrown their original utility, yet LIMS is too brittle to accommodate adjustments.

Disconnected information

Rolled out in silos, LIMS typically house data within a standalone system that doesn't connect intelligence or processes with other R&D solutions.



Onerous for IT to maintain

Antiquated infrastructure for LIMS requires significant IT resources to maintain; IT spends time regularly patching up data and connectivity issues.

Poll What are the biggest challenges as teams move into production?

- 1. Missing context from upstream activities
- 2. Time and resources involved in handoffs across systems
- 3. Understanding compliance requirements
- 4. Consistent tracking
- 5. Getting key insights on sample and program performance
- 6. All of the above

By contrast, the Benchling R&D Cloud is biology's modern LIMS.

Built for biology

Benchling was specifically built for the complexities and nuances involved in designing, testing, and producing today's large molecules.



Connected

Scientists can work in shared digital solution to advance R&D with minimal friction. Collaboration is an integrated part of the workflow rather than a separate set of tasks.

Adaptable

Benchling supports process changes over time. As process insights and opportunities arise, Benchling allows development teams to take advantage of methods innovation.

Modern technology

Benchling users share a powerful & simple unified cloud-native workspace. With regular release updates, users always have the most advanced functionality.

Design, test, and produce complex biomolecules in Benchling R&D Cloud

For non- and GxP-compliant use cases



Poll Which of these use cases best fit your LIMS needs?

- 1. Handoffs across teams
- 2. Tracking samples
- 3. Ensuring compliance and data integrity
- 4. Sharing scientific and operational data
- 5. Multiple needs from above options

9

Optimize handoffs across scientists and teams

Design workflows easily

Provide context for work done

Track progress and unblock bottlenecks

2	Workflows / Transfection team	n task qu	nene 🔺 🌣						
•	Q Search			Type: 📾	Transfection 🔹 \Xi				
۹	 1-25 of 33 items 	101							
4	D ID	¥	Assignee	\downarrow	Status \downarrow	Scheduled on \downarrow	Plasmid lot tube	Plasmid lot	Nost cell
	➔ TFX10-T4		🔮 vineet		C In Progress	5/13/2022	0 t121	🗐 p004-002	© CELL01
	10 TFX10-T3		🚷 ashoka		C In Progress	4/28/2022	ij t120	🔲 p003-003	© CELLO2
8	TFX10-T2		🚷 ashoka		Completed	4/28/2022	0 t119	🗐 p002-002	© CELLO2
~	10 TFX10-T1		🌸 ashoka		8 Failed	4/28/2022	U 1118	🔲 p001-003	© CELL01
2	TFX8-T11		Jia Liu		O Pending	5/19/2022	8 t117	🗐 p006-006	© CELL01
ш	TFX8-T10		Jia Liu		O Pending	5/19/2022	0 t114	🗐 p006-005	© CELL01
83	TFX8-T9		Ø mimi		Completed	5/23/2022	0 t111	🔳 p006-004	© CELL01
	TFX8-T8		🔮 vineet		C In Progress	5/13/2022	U 1116	🗐 p007-007	© CELL01
	 TFX8-T7 		🔮 vineet		🕒 In Progress	5/13/2022	0 t113	p007-006	◎ CELL01
	➔ TFX8-T6		🔮 vineet		C In Progress	5/13/2022	8 t110	🔲 p007-005	© CELL01
	➔ TFX8-T5		Ø mimi		C In Progress	5/23/2022	0 t115	🗐 p010-007	© CELLO2
	➔ TFX8-T4		Ø mimi		O Pending	5/23/2022	0 t112	■ p010-006	© CELLO2
	⇒ TFX8-T3		D dane		O Pending	5/26/2022	# 1109	🗐 p010-005	© CELLO2
					-				

Track samples throughout lifecycle

Register samples into shared data set

Integrate sample tests

Increase inventory utilization

Maintain sample history across R&D

			NGS	Run QC A	nalvsis 🧊			
NGSRUN_ID006 Registry		◙ ≓ 🔣 🖬 …	0	NGS Run I		ID006		
Authors	Project Location							
Junn	📗 Sequencing Runs 📩		1	≓ LIB385	- i5-00003	- 17-00008	- DNA193	
Registry IDs	Created		2	≓ LIB386	- i5-00001	- i7-00005	- DNA194	
NGSRUN_ID006	2/15/2021 03:37 PM		3	≓ LIB429	- i5-00004	- 17-00006	- DNA237	
30-3EG			4	≓ LIB387	- i5-00004	- i7-00005	- DNA195	
Aliases 🕇			5	≓ LIB388	- i5-00002	- 17-00006	- DNA196	
This entity has no aliases.			6	≓ LIB389	- i5-00004	- i7-00006	- DNA197	
			7	≓ LIB390	- i5-00003	- 17-00006	- DNA198	
Schema		Edit	8	≓ LIB391	- i5-00004	- 17-00006	- DNA199	
Experiment Creation	~	Luit	9	≓ LIB392	= i5-00001	- i7-00005	- DNA200	
Cannot change schema of	registered entities							
FIELD	VALUE		San	nple Reads				
Project	Project A			10000000				
Initials	JC			9000000				
Sequencing Type	DNA			7000000				
	101000000		spe	6000000				
Flow Cell	S JCMSFC2020		of Re	5000000				
Sequencer	III MiSeq-0511		*	3000000		lum.		
Data Completed	2/17/2021			2000000	lin,			
Data Completed	2/17/2021			1000000	llim.			

Ensure compliance and data integrity

Collaborate in compliant environment

Manage lock down procedures

Maintain traceability

Validate system updates easily

				ويصفح والمحاص	يندورا — يتجريا -							0.000	
Endotoxin Assay	×												
ADD PROTOCOL NOT	JTOCOL NOTES METADATA REVIEW										🛛 Share		
ê ▼ Insert × H	* B I <u>U</u> S	% φ A * x _i	$x_1 \equiv \equiv \infty$	More -							4	* *	©
-													
End	lotoxin	Assay							EXP2200040	C In progress	s	•	0
THURSDA	Y, 2/10/2022												
500	for accase												
SOP Test pr	SUP TOT ASSAY Test procedure: D Endotoxin Test - QC SOP -P92812 Rev 05/05/2021												
End	otoxin Test:	1. d. b. ab											
	ach assay should inc	lude both a positive	control and a negativ	e control (LAL Reage	ent Water).								
• • • I	 Sample: Protein A, 1 mg/ml in PBS, pH 7.4. It is purified from <i>E, coli</i> sonicate by Ni-NTA resin. Dilution by LAL water: 1: 200,000, 1: 400,000, 1: 800,000. 												
	 ✓ Ca ✓ an ✓ Ac ✓ Af ✓ Ac ✓ Re 	refully dispense 100 d label them as stan dd 100 μl of reconstit ter proper incubatio dd 500 μl of reconsti ead the absorbance o	µl of standards, samp dard 1, 2, 3, 4, sample tuted LAL to each vial n, add 100 µl of recon tuted stop solution of each reaction at 545	oles and LAL reagent 1, 2, etc. and blank. S I. Cap the vials and m istituted chromogeni 5 nm.	water into different er iample should be mixer ix well by swirling gen c substrate solution to	idotoxin-free vials d thoroughly for 30 sec tly. each vial.	onds with a vortex mix	xer too. Avoid foaming.					
Endoto	xin concentration in	this sample is: from	200,000×0.25 to 400	0,000×0.25, that is, fr	om 50,000 to 100,000) EU/ml.							
Assa	y Results												
Data	from Endotoxin	Test											
	nter data from instru	ument:											
I R	sults Endotoxin A	ssav 1 +						0	이 * 날 * 19	🖩 Submit	1.		
5	Entity	Lipid ID	# Dilution	# EU/mL	Q. Lipid Type	Aa Assay Kit Lot	Aa PASS/FAIL						
1													
=													
					_								



Gilead Partners with Benchling to improve large molecule bioprocess development

<mark>Goal</mark>

Improve scientist productivity, collaboration, and access to data insights in order to increase efficiency and predictability of Gilead's large molecule process development. "At Gilead, we're committed to creating a healthier world for everyone by discovering, developing and delivering medicines for life-threatening diseases. This work requires managing highly complex, multi-dimensional data and necessitates technology partners that can support the scale and complexity of the data created by high-throughput biology. We selected Benchling as a partner because it's built for biology. By capturing structured data in Benchling, our scientists are empowered to ask challenging questions and uncover new insights."



Peter Huang

Executive Director, Pharmaceutical Development & Manufacturing Information Systems

2x improvement in ease of data sharing within and across teams 63% reduction in time spent on data capture, search, and collection >2x

improvement in ease of study review and forecast approval

75%

improvement in ability to track sample and experimental data

Benchling investment priorities



Thank you

